<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888715</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWN12088103</org_study_id>
    <nct_id>NCT04888715</nct_id>
  </id_info>
  <brief_title>To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers</brief_title>
  <official_title>An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between &quot;DWN12088&quot; and &quot;Pirfenidone&quot; or &quot;Nintedanib&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions&#xD;
      between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is an open label, 2-part, one-sequence, 3-period study to evaluate&#xD;
      drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Actual">August 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Pirfenidone and DWN12088</measure>
    <time_frame>0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour</time_frame>
    <description>Cmax of Pirfenidone and DWN12088</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Pirfenidone and DWN12088</measure>
    <time_frame>0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour</time_frame>
    <description>AUC of Pirfenidone and DWN12088</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Nintedanib and DWN12088</measure>
    <time_frame>0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour</time_frame>
    <description>Cmax of Nintedanib and DWN12088</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Nintedanib and DWN12088</measure>
    <time_frame>0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour</time_frame>
    <description>AUC of Nintedanib and DWN12088</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>DWN12088 and Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWN12088 and Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWN12088</intervention_name>
    <description>Prolyl-tRNA synthetase (PRS) inhibitor</description>
    <arm_group_label>DWN12088 and Nintedanib</arm_group_label>
    <arm_group_label>DWN12088 and Pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone</description>
    <arm_group_label>DWN12088 and Pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib</description>
    <arm_group_label>DWN12088 and Nintedanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged ≥ 19 and ≤ 55 years at screening&#xD;
&#xD;
          -  Subjects who voluntarily decided to participate in the study and provided written&#xD;
             consent to after receiving a detailed explanation on this study and fully&#xD;
             understanding the information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who received another investigational agent in another study (including&#xD;
             bioequivalence study) within 180 days prior to the first dose of the IP (The end of&#xD;
             prior study participation will be the date of the last dose, and the days will be&#xD;
             counted from the next day [1 day].)&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA UNITERSITY BUNDANG MEDICAL CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cha Unitersity Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13520</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

